Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Starpharma Holdings Limited ( (AU:SPL) ) is now available.
Starpharma has entered into a research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset using its proprietary DEP® platform technology. This partnership is a significant milestone for Starpharma, marking its first radiopharmaceutical collaboration and the advancement of its Star Navigator program into a formal research collaboration. The agreement allows Starpharma to receive R&D service and manufacturing fees, with the potential for substantial financial gains through licensing options, success-based milestones, and royalties. This collaboration highlights the potential of dendrimers in radiopharmaceutical drug development and expands Starpharma’s commercial opportunities without impacting its internal development efforts.
More about Starpharma Holdings Limited
Starpharma Holdings Limited is an innovative biotechnology company specializing in dendrimer technology. The company focuses on developing high-value, differentiated assets and forming strategic partnerships, particularly in the field of radiopharmaceuticals, supported by robust scientific data.
Average Trading Volume: 805,090
Technical Sentiment Signal: Hold
Current Market Cap: A$92.01M
Find detailed analytics on SPL stock on TipRanks’ Stock Analysis page.